Changeflow GovPing Pharma & Drug Safety Prostate Cancer Combination Therapy, Abirateron...
Routine Notice Added Final

Prostate Cancer Combination Therapy, Abiraterone Acetate, Niraparib

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260097048A1 for a combination therapy of abiraterone acetate and niraparib for treating prostate cancer. The application was filed on December 11, 2025, by inventors Thomas Ronald A. Quinten and colleagues, covering free-dose and fixed-dose combinations and methods of treatment.

What changed

USPTO published patent application US20260097048A1 for a combination therapy of abiraterone acetate and niraparib for treating prostate cancer. The application covers free-dose and fixed-dose combinations and methods of use for prostate cancer treatment. Inventors include Thomas Ronald A. Quinten, Urbain Alfons C. Delaet, Philip Erna H. Heyns, and others.\n\nPharmaceutical manufacturers and oncology researchers should monitor published patent applications as they may indicate future competitive developments and potential freedom-to-operate considerations. Patent applications establish priority rights and inform the public of claimed subject matter.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB

Application US20260097048A1 Kind: A1 Apr 09, 2026

Inventors

Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK

Abstract

The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.

CPC Classifications

A61K 31/58 A61K 9/1617 A61K 9/1635 A61K 9/1694 A61K 9/2009 A61K 9/2013 A61K 9/2018 A61K 9/2027 A61K 9/2054 A61K 9/28 A61K 31/454 A61K 31/573 A61K 38/25 A61P 13/08 A61P 15/00 A61P 35/00 A61P 35/04

Filing Date

2025-12-11

Application No.

19415909

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
December 11th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097048A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Pharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!